Skip to main content
Fig. 8 | BMC Proceedings

Fig. 8

From: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report

Fig. 8

Summary of the survey results for each of the clinical statements voted by the participating physicians. ACEi, angiotensin-converting enzyme; CVRF, Cardiovascular risk factors; FDC, fixed-dose combination; HT, hypertension; LDL-c, low density lipoprotein cholesterol; MACE, major adverse cardiovascular event

Back to article page